Page last updated: 2024-09-03

imatinib mesylate and Jaundice

imatinib mesylate has been researched along with Jaundice in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Araki, K; Harimoto, N; Hoshino, T; Ishii, N; Kakizaki, S; Kudo, T; Masuda, T; Naganuma, A; Ogawa, T; Ogawa, Y; Shirabe, K; Suzuki, Y; Tateno, K; Tateyama, Y; Uehara, S; Yasuoka, H	1
Andraus, W; D'Albuquerque, LC; Lima, FR; Nacif, LS; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR	1
Catania, C; Curigliano, G; Danesi, R; De Braud, F; De Pas, T	1

Reviews

1 review(s) available for imatinib mesylate and Jaundice

Article	Year
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. Journal of medical case reports, 2018, Mar-10, Volume: 12, Issue:1 Topics: Abdominal Pain; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Immunosuppression Therapy; Jaundice; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Nausea; Protein Kinase Inhibitors; Time Factors; Treatment Outcome	2018

Article

Year

Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.

Journal of medical case reports, 2018, Mar-10, Volume: 12, Issue:1

Topics: Abdominal Pain; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Immunosuppression Therapy; Jaundice; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Nausea; Protein Kinase Inhibitors; Time Factors; Treatment Outcome

2018

Other Studies

2 other study(ies) available for imatinib mesylate and Jaundice

Article	Year
Imatinib and nutritional support can make successful treatment for a case of huge liver metastasis of duodenal gastrointestinal stromal tumor that initially showed jaundice and cachexia. Clinical journal of gastroenterology, 2021, Volume: 14, Issue:2 Topics: Adult; Antineoplastic Agents; Cachexia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Neoplasm Recurrence, Local; Nutritional Support	2021
Imatinib administration in two patients with liver metastases from GIST and severe jaundice. British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Male; Piperazines; Pyrimidines; Stromal Cells; Treatment Outcome	2003

Article

Year

Imatinib and nutritional support can make successful treatment for a case of huge liver metastasis of duodenal gastrointestinal stromal tumor that initially showed jaundice and cachexia.

Clinical journal of gastroenterology, 2021, Volume: 14, Issue:2

Topics: Adult; Antineoplastic Agents; Cachexia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Neoplasm Recurrence, Local; Nutritional Support

2021

Imatinib administration in two patients with liver metastases from GIST and severe jaundice.

British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Male; Piperazines; Pyrimidines; Stromal Cells; Treatment Outcome

2003